212 | SAVE (SAFE ACCELERATED VENETOCLAX ESCALATION): RESULTS OF A PROSPECTIVE, PHASE Ib STUDY OF VENETOCLAX WITH AN ACCELERATED DOSE RAMP‐UP IN PATIENTS WITH CLL
Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Josie Montegaard(Dana-Farber Cancer Institute), Alexander Kim(Dana-Farber Cancer Institute), Il Young Ahn(Dana-Farber Cancer Institute), Robert Black(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Reid W. Merryman(Harvard University), Marykate Kilcommons(Dana-Farber Cancer Institute), Yi Ren(First People's Hospital of Chongqing), David C. Fisher(Dana-Farber Cancer Institute), Samantha Normilus(Dana-Farber Cancer Institute), Chris Carey(University of Brighton), M. Kniezewski(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University)
Cited by 0
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890